



Press Release

Oncobit Announces Appointment of Bram Goorden as Chairman

Zurich, Switzerland - 23.06.2026 – Oncobit AG announces changes to its Board of Directors following its Annual General Meeting.

Bram Goorden has been elected Chairman of the Board, succeeding Dr. Ruedi Gygax, who has served as Chairman for the past five years. Following his term as Chairman, Dr. Gygax will continue to support the company as Board Advisor. Prof. Mitch Levesque has stepped down from the Board of Directors and will remain closely involved with Oncobit.

The Board believes that Mr. Goorden's extensive experience in precision medicine, molecular diagnostics and international commercialization makes him ideally suited to guide Oncobit through its next phase of growth. In addition to his role at Oncobit, Bram Goorden also serves as CEO and Executive Director of IXICO plc, a publicly listed precision medicine company specializing in imaging and biomarker analytics for neurodegenerative diseases.

"Bram has already made a significant contribution since joining the Board in 2024," said Dr. Claudia Scheckel, CEO and Co-Founder of Oncobit. "His experience in scaling precision medicine businesses and driving commercial adoption will be invaluable as we continue to expand our commercial activities and strategic partnerships."

The Board and management team would also like to express their sincere gratitude to Dr. Gygax for his dedicated service as Chairman. During a critical chapter of Oncobit's development, his dedication, perseverance and commitment helped shape the company it is today.

"I am honored to assume the role of Chairman at this exciting stage in Oncobit's journey," said Bram Goorden. "With the recent launch of our first solution in the US market, growing adoption of our clinical solutions, and increasing collaboration with assay development and biopharma partners, Oncobit is well positioned for its next phase of growth. I look forward to working closely with Claudia, the Board and the team to further expand Oncobit's impact in precision oncology."

About

Oncobit is a Swiss precision oncology company advancing personalized cancer monitoring through its proprietary Oncobit™ PM liquid biopsy platform. By combining highly sensitive molecular assays with cloud-based software, Oncobit delivers standardized, data-driven insights that support treatment decisions and improve patient management.

Oncobit's current focus is melanoma with a broader pipeline of cancer indications under development. Its portfolio includes IVDR-certified liquid biopsy diagnostic solutions available in Europe both as decentralized kit-based solutions and through its Swiss-based central laboratory. In the United States, Oncobit's technology is commercially available as a testing service through its partnership with TrilliumBio. Oncobit also collaborates with a growing network of assay development and biopharma partners to expand the reach of its platform across additional indications.

Contact

Oncobit AG
Dr. Claudia Scheckel, CEO, Oncobit
+41 78 850 07 87
claudia.scheckel@oncobit.com
<https://oncobit.com>